Lucentis Biosimilar To Be Sold To Emerging Markets By Xbrane Biopharma
This article was originally published in Scrip
Executive Summary
Stockholm-based Xbrane Biopharma plans to be the first to sell a biosimilar version of Lucentis in Iran as part of its strategy to leverage patent gaps in emerging markets for high-priced drugs.
You may also be interested in...
Samsung Bioepis Joins Biosimilar Lucentis Fray As It Unveils Phase III Plans
Samsung Bioepis has said it is preparing a Phase III trial with a proposed ranibizumab biosimilar, joining a number of players developing biosimilar versions of the ophthalmic use drug, which loses its first major patents in the next few years.
Samsung Bioepis Joins Biosimilar Lucentis Fray As It Unveils Phase III Plans
Samsung Bioepis has said it is preparing a Phase III trial with a proposed ranibizumab biosimilar, joining a number of players developing biosimilar versions of the ophthalmic use drug, which loses its first major patents in the next few years.
BiocurePharm Looks Beyond North America Via Canada IPO
With a business model that sets it apart from other South Korean bioventures, BiocurePharm plans to set up manufacturing facilities in North America and worldwide with local partners, and is launching a Canadian IPO in a bid to transform into a truly multinational operation, its CEO says.